Isolazine Tablet contains a combination of Isosorbide Dinitrate (20 mg) and Hydralazine (37.5 mg), utilized primarily in the management of heart failure and hypertension. Isosorbide Dinitrate is a nitrate vasodilator that acts by releasing nitric oxide, leading to relaxation of vascular smooth muscle, predominantly in the venous system, thereby reducing preload and myocardial oxygen demand. Hydralazine is a direct-acting arterial vasodilator that decreases systemic vascular resistance and afterload by relaxing arteriolar smooth muscle. The synergistic effect of these agents improves cardiac output and reduces blood pressure, making Isolazine effective in patients with congestive heart failure, particularly those intolerant to ACE inhibitors or with persistent symptoms despite standard therapy. This combination is also beneficial in managing hypertension, especially in populations with salt-sensitive or resistant hypertension. Isolazine should be administered under medical supervision, with dosage adjustments based on therapeutic response and tolerance. Common side effects may include headache, dizziness, hypotension, and reflex tachycardia. Caution is advised in patients with hypotension, volume depletion, or hypersensitivity to nitrates or hydralazine. Regular monitoring of blood pressure and clinical status is recommended to optimize treatment outcomes and minimize adverse effects.